5 ms·
This has interesting implications when we consider how much money drug companies “should” be paid for inventing important new life-saving medicines. I frequent
by sokoloff 5y ago
This has interesting implications when we consider how much money drug companies “should” be paid for inventing important new life-saving medicines.
I frequently hear/read complaints of "that's outrageous [that this medicine costs $X]!"
Well, maybe it is; maybe it isn't, but if you make sure it costs $X/100, I can be pretty sure you'll get less drug R&D.
- hellbannedguy 5y agoThat's fine for new drugs. Not for generic drugs. And let us buy our meds out of country. (And buying out generic drug manufactures should other drug companies in order to decrease competition is not cool either.)
- semi-extrinsic 5y agoPharma companies in the US spend about twice as much on advertising as they do on R&D [1]. Recent data compiled by the House Oversight Committee shows the biggest pharma companies spent $56 billion more on stock buybacks and dividends than they did on R&D over the past five years [2]. Very little of the ridiculous prices that US citizens pay for medicine (directly or via insurance) actually goes towards R&D. [1] https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0050001 https://journals.plos.org/plosmedicine/article?id=10.1371/jo... [2] https://oversight.house.gov/sites/democrats.oversight.house.gov/files/COR%20Staff%20Report%20-%20Pharmaceutical%20Industry%20Buybacks%20Dividends%20Compared%20to%20Research.pdf https://oversight.house.gov/sites/democrats.oversight.house....
- greeneggs 5y agoYour first link is from 2008, and analyzes data from 2004. I don't see how this proves anything, or even suggests much, about the industry today. Your second link shows that the pharma companies spend almost as much on R&D as on stock dividends and buybacks. Is there any other industry that spends as much on R&D? Apple, for instance, seems to be spending ~6x as much on stock buybacks and dividends as on R&D (approximately, based on the first Google hits). Even your own links contradict your claim that very little goes to R&D.
- ricardobeat 5y agoThis is not a dick measuring contest. The comment was challenging the notion that pharmaceuticals companies spending the majority of their cash on advertising and stock buybacks is a desired outcome. The specific numbers, especially across industries, are meaningless.
- Lhiw 5y agoWe're not talking about government action forcing apple to sell iPads for near cost. We're talking about whether using the governments scale to negotiate better pricing is going to put them out of business or in this arguments case whether it will reduce their spending on r&d. The idea that it would is silly at best given how much they spend on marketing compared to r&d. It also ignores how much the government gives them to fund new research with nothing in return, hello Moderna you Brandon loving fucks.
- anamax 5y agoAdvertising includes drug samples given to doctors, which many/most of them give to patients who can't afford said drugs. How many of them are you willing to cut off?
- hypertele-Xii 5y agoFree samples over R&D? In what world does that sound... sound?
- Afton 5y agoIn order to make the drug more affordable? I mean... all of them? Maybe I'm not understanding your point?
- Retric 5y agoThose free samples very much make treatment less affordable. They don’t need to hand out samples when their treatment is the only option, they need to advertise to out compete generics. It’s shockingly effective, look at say prescriptions for patented opioids vs the vast numbers of equally effective generics. Doctors are extremely susceptible to advertising just like most people, the difference is it’s not their money being spent.
- emodendroket 5y agoIn the case of doctors it's more high-touch than plain old ads anyway. The representative stops by and chats them up, maybe they get some sponsored continuing education (which is of course designed to push expensive products), etc.
- catawbasam 5y agoAnd the reps are often smoking hot, so docs don't mind making a bit of time for conversation.
- geoduck14 5y agoFun fact: Female secretaries (or other "gatekeepers") are less likely to let hot female sales people back to the doctor.
- refurb 5y agoTerrible take. Your first source vaguely tries to estimate promotional spending (not advertising as you deceitfully claim). Promotional spend has a positive ROI (or you wouldn’t do it). So spending $1B in promotion gets your $1B+ in sales (it’s self funding). Plus stock buybacks and dividends are being criticized? Returning money to investors is “bad”? Who do you think provides capital for drug development? The Grenadier Guards?
- jiggawatts 5y ago$1B in R&D can often result in $100B in sales, so it is "even more" self-funding. “Don’t tell me where your priorities are. Show me where you spend your money and I’ll tell you what they are.” – James W. Frick
- s1artibartfast 5y agoAre you claiming that Pharma companies don't want to make money and are therefore not investing more in R&D?
- catlikesshrimp 5y agoPrice is not defined by costs. You adjust prices for maximum profit, as in the k of (h,k) of a quadratic equation. If you can produce a drug for 1$ a dose and you can sell it for 100$ at most without losing customers, you do that. If your product costs are too high, you don't advertise. You sell the drug to the government as an "orphan drug".
- Retric 5y agoPrice very much depends on cost, the goal is profit maximization not maximizing revenue. Suppose you can sell 1 million sandwiches at 5$ or 1/2 a million at 6$ which you price depends on your cost of production. If it’s costing you less than 4$ you pick the first option if it’s more than 4$ and less than 6$ you pick the second. Though in the real world costs aren’t independent of sales so it’s even more complicated. It’s only when you get extreme markups from a guaranteed monopoly that you can approximate things as revenue maximization. Also, drug R&D numbers are extremely inflated as among other things it’s got tax advantages.
- HWR_14 5y agoR&D is actually usually done outside of the major drug companies and is funded by the government. So I doubt it really will effect it. And most price hikes lately have been in pre-existing drugs. It's interesting to note that the Pfizer, AstroZeneca and J&J vaccines were all invented by 3rd parties.
- pfisherman 5y agoEarly stage R&D is the part that typically happens outside of big pharma, though all the big companies have their own proprietary early stage efforts/portfolios. Even then govt funded stuff is mostly preclinical. Start ups mostly cover anything from animal studies to phase 1 / 2. Late stage R&D, manufacturing, and marketing is extremely capital intensive and complex and is mostly done by large pharma companies, who either license the asset or enter some sort of partnership with the IP holder. And I am including regulatory approval, demonstrating value to payers, etc under marketing (e.g. it is not just advertising).
- emodendroket 5y agoIt's not really this simple since you can directly subsidize/incentivize R&D if that's the goal.
- Alex3917 5y ago> I can be pretty sure you'll get less drug R&D. You'd get more R&D. There were way more new drugs released before Bayh-Dole.
- nradov 5y agoMaybe not. Most of the low hanging fruit. It's becoming much more difficult to find novel small molecule drugs. The possibilities are finite.